Mesenchymal stem cell-derived exosomes for the treatment of pulmonary diseases

Emission of air pollutants, long-term tobacco use and advanced age can cause a variety of pulmonary diseases, which are associated with high mortality rates and pose a serious threat to human health. Recent studies have found that mesenchymal stem cells (MSCs) can independently migrate to the injured site, repair damaged tissues and participate in the regulation of systemic inflammation and immune response. These properties make the use of MSCs a promising therapeutic approach for the treatment of pulmonary disease, resulting in remarkable future clinical prospects. Exosomes are a type of extracellular vesicles which can participate in various physiological activities by regulating intercellular communication. Exosomes released into the extracellular space can also affect the host immune system. MSC-derived exosomes carry bioactive molecules such as proteins, lipids, mRNAs and microRNAs, which have higher safety profile and therapeutic potential compared to cell-based therapies. In this review, we summarize and discuss the preclinical and clinical studies conducted in recent years and the mechanisms of action of MSC-derived exosomes in the treatment of pulmonary diseases.

[1]  M. M. Mokhber Dezfouli,et al.  Mesenchymal stem/stromal cells: the therapeutic effects in animal models of acute pulmonary diseases , 2020, Respiratory Research.

[2]  V. Jha,et al.  Urinary exosomes: Potential biomarkers for diabetic nephropathy , 2020, Nephrology.

[3]  X. Wang.  MSCs transplantation may be a potential therapeutic strategy for COVID-19 treatment. , 2020, European review for medical and pharmacological sciences.

[4]  Falin Chen,et al.  Circular RNAs expression profiles in plasma exosomes from early‐stage lung adenocarcinoma and the potential biomarkers , 2020, Journal of cellular biochemistry.

[5]  Yu Jiang,et al.  Exosomes as potential sources of biomarkers in colorectal cancer. , 2020, Cancer letters.

[6]  J. Qu,et al.  Effect of hCMSCs and liraglutide combination in ALI through cAMP/PKAc/β-catenin signaling pathway , 2020, Stem Cell Research & Therapy.

[7]  Guihua Chen,et al.  Exosomes derived from microRNA-30b-3p-overexpressing mesenchymal stem cells protect against lipopolysaccharide-induced acute lung injury by inhibiting SAA3. , 2019, Experimental cell research.

[8]  Jianying Li,et al.  Mesenchymal stem cell-derived exosomes as a nanotherapeutic agent for amelioration of inflammation-induced astrocyte alterations in mice , 2019, Theranostics.

[9]  Yu Zhang,et al.  Exosomes derived from mesenchymal stem cells reverse EMT via TGF-β1/Smad pathway and promote repair of damaged endometrium , 2019, Stem Cell Research & Therapy.

[10]  Qing Luo,et al.  Mesenchymal Stem Cell Migration and Tissue Repair , 2019, Cells.

[11]  Zhong Chen,et al.  Mesenchymal stromal cells‐derived exosomes alleviate ischemia/reperfusion injury in mouse lung by transporting anti‐apoptotic miR‐21‐5p , 2019, European journal of pharmacology.

[12]  N. Rouas-Freiss,et al.  Biological functions of mesenchymal stem cells and clinical implications , 2019, Cellular and Molecular Life Sciences.

[13]  S. H. Lee,et al.  Factors associated with chronic obstructive pulmonary disease exacerbation, based on big data analysis , 2019, Scientific Reports.

[14]  Q. Bian,et al.  Exosomal microRNA-21 derived from bronchial epithelial cells is involved in aberrant epithelium-fibroblast cross-talk in COPD induced by cigarette smoking , 2018, Theranostics.

[15]  V. Bhandari,et al.  Early gestational mesenchymal stem cell secretome attenuates experimental bronchopulmonary dysplasia in part via exosome-associated factor TSG-6 , 2018, Stem Cell Research & Therapy.

[16]  R. Sadikot,et al.  Bronchoalveolar Lavage Exosomes in Lipopolysaccharide-induced Septic Lung Injury. , 2018, Journal of visualized experiments : JoVE.

[17]  H. Salehi,et al.  Chronic obstructive pulmonary disease: MicroRNAs and exosomes as new diagnostic and therapeutic biomarkers , 2018, Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences.

[18]  S. Archer,et al.  Pulmonary arterial hypertension: pathogenesis and clinical management , 2018, British Medical Journal.

[19]  Chengping Hu,et al.  Extracellular Vesicle MicroRNA Transfer in Lung Diseases , 2017, Front. Physiol..

[20]  Y. Lau,et al.  PD‐1/PD‐L1 Pathway Mediates the Alleviation of Pulmonary Fibrosis by Human Mesenchymal Stem Cells in Humanized Mice , 2017, American journal of respiratory cell and molecular biology.

[21]  Ying Lin,et al.  Mesenchymal stem cell exosomes promote immunosuppression of regulatory T cells in asthma , 2017, Experimental cell research.

[22]  Haibo Zhang,et al.  Hypoxia-preconditioned mesenchymal stem cells ameliorate ischemia/reperfusion-induced lung injury , 2017 .

[23]  J. Dhawan,et al.  Exosomes: mobile platforms for targeted and synergistic signaling across cell boundaries , 2016, Cellular and Molecular Life Sciences.

[24]  M. Pittenger,et al.  Concise Review: MSC‐Derived Exosomes for Cell‐Free Therapy , 2017, Stem cells.

[25]  S. Berkelhamer,et al.  Bronchopulmonary Dysplasia: Chronic Lung Disease of Infancy and Long-Term Pulmonary Outcomes , 2017, Journal of clinical medicine.

[26]  H. Choi,et al.  Lung epithelial cell-derived extracellular vesicles activate macrophage-mediated inflammatory responses via ROCK1 pathway , 2015, Cell Death and Disease.

[27]  M. Gladwin,et al.  Pulmonary arterial hypertension: the clinical syndrome. , 2014, Circulation research.

[28]  Ioanna Kougioumtzi,et al.  Airway inflammation in chronic obstructive pulmonary disease. , 2014, Journal of thoracic disease.

[29]  B. Yu,et al.  Exosomes Derived from Mesenchymal Stem Cells , 2014, International journal of molecular sciences.

[30]  M. Matthay,et al.  Human Mesenchymal Stem Cell Microvesicles for Treatment of Escherichia coli Endotoxin‐Induced Acute Lung Injury in Mice , 2014, Stem cells.

[31]  Clotilde Théry,et al.  Analysis of ESCRT functions in exosome biogenesis, composition and secretion highlights the heterogeneity of extracellular vesicles , 2013, Journal of Cell Science.

[32]  S. Gabrielsson,et al.  Altered microRNA profiles in bronchoalveolar lavage fluid exosomes in asthmatic patients. , 2013, The Journal of allergy and clinical immunology.

[33]  Changjin Lee,et al.  Exosomes Mediate the Cytoprotective Action of Mesenchymal Stromal Cells on Hypoxia-Induced Pulmonary Hypertension , 2012, Circulation.

[34]  A. M. Herrera,et al.  Fibrotic Response of Tissue Remodeling in COPD , 2011, Lung.

[35]  N. Ambalavanan,et al.  Pulmonary hypertension in bronchopulmonary dysplasia. , 2009, Birth defects research. Part A, Clinical and molecular teratology.

[36]  J. P. Shinnick.  Chronic obstructive pulmonary disease- an overview. , 1981, The Journal of the American Osteopathic Association.

[37]  A. Marttos,et al.  Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients with Acute Respiratory Distress Syndrome (ARDS). , 2020, CellR4-- repair, replacement, regeneration, & reprogramming.

[38]  M. Ericsson,et al.  Mesenchymal Stromal Cell Exosomes Ameliorate Experimental Bronchopulmonary Dysplasia and Restore Lung Function through Macrophage Immunomodulation , 2018, American journal of respiratory and critical care medicine.

[39]  A. Mendez,et al.  Differences in exosome content of human adipose tissue processed by non-enzymatic and enzymatic methods , 2015 .

[40]  P. Robbins,et al.  Exosomes in the Pathogenesis, Diagnosis and Treatment of Pancreatic Diseases. , 2014, CellR4-- repair, replacement, regeneration, & reprogramming.